Premium
Application of a biodegradable macromolecular contrast agent in dynamic contrast‐enhanced MRI for assessing the efficacy of indocyanine green‐enhanced photothermal cancer therapy
Author(s) -
Feng Yi,
Emerson Lyska,
Jeong EunKee,
Parker Dennis L.,
Lu ZhengRong
Publication year - 2009
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.21838
Subject(s) - indocyanine green , magnetic resonance imaging , photothermal therapy , medicine , cystamine , dynamic contrast , dynamic contrast enhanced mri , cancer , nuclear medicine , biomedical engineering , materials science , pathology , radiology , immunology , nanotechnology
Purpose To investigate the effectiveness of a polydisulfide‐based biodegradable macromolecular contrast agent, (Gd‐DTPA)‐cystamine copolymers (GDCC), in assessing the efficacy of indocyanine green‐enhanced photothermal cancer therapy using dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI). Materials and Methods Breast cancer xenografts in mice were injected with indocyanine green and irradiated with a laser. The efficacy was assessed using DCE‐MRI with GDCC of 40 kDa (GDCC‐40) at 4 hours and 7 days after the treatment. The uptake of GDCC‐40 by the tumors was fit to a two‐compartment model to obtain tumor vascular parameters, including fractional plasma volume (f PV ), endothelium transfer coefficient (K PS ), and permeability surface area product (PS). Results GDCC‐40 resulted in similar tumor vascular parameters at three doses, with larger standard deviations at lower doses. The values of f PV , K PS , and PS of the treated tumors were smaller ( P < 0.05) than those of untreated tumors at 4 hours after the treatment and recovered to pretreatment values ( P > 0.05) at 7 days after the treatment. Conclusion DCE‐MRI with GDCC‐40 is effective for assessing tumor early response to dye‐enhanced photothermal therapy and detecting tumor relapse after the treatment. GDCC‐40 has a potential to noninvasively monitor anticancer therapies with DCE‐MRI. J. Magn. Reson. Imaging 2009;30:401–406. © 2009 Wiley‐Liss, Inc.